

Modern Slavery Act Statement for the period from 1 January 2023 to 31 December 2023

Introduction

This Modern Slavery Act Statement ("**Statement**") is made pursuant to Part 6, Section 54 of the Modern Slavery Act 2015 (Transparency in Supply Chains) and applies to the following legal entities:

1. Abbott Laboratories Limited;
2. Abbott Diabetes Care Limited;
3. Abbott Medical U.K. Limited; and
4. Abbott Rapid Diagnostics Limited.

Together, these entities are referred to as "**Abbott UK**" or "**we**". Abbott Laboratories is committed to upholding the fundamental principles of human rights, labour, and environmental protection to ensure long-term business success for Abbott, and to improve lives around the world. Our Position Statement on Human Rights sets out our commitment to human rights and is supported by our Code of Conduct and Supplier Guidelines as it relates to our operations and supply chain, respectively.¹ As set out in our Position Statement on Human Rights, Abbott believes in the dignity of every human being and respects individual rights as set forth in the United Nations' Universal Declaration of Human Rights and Guiding Principles on Business and Human Rights (UNGPs).

Abbott recognises that companies play a supporting role in promoting human rights within their spheres of influence. We contribute to the fulfilment of human rights through compliance with laws and regulations wherever we operate, as well as through our policies and programmes. The principles referenced in Abbott's Position Statement on Human Rights are reflected in our employment, ethics, and procurement policies, which are designed to promote, protect, and respect human rights within Abbott and with our suppliers.

Our Structure

Structure and Business

Abbott Laboratories ("Abbott"), headquartered in Abbott Park, Illinois USA, is the ultimate parent company of each of the entities comprising Abbott UK. Abbott is a global diversified healthcare company with a central purpose of helping people live their healthiest possible lives, through our broad portfolio of products and technologies. The Abbott global business is organised into four main divisions: Medical Devices, Diagnostics, Nutrition and Medicines. We do not sell medicines in the UK.

As of the date of this Statement, we have approximately 114,000 employees worldwide and operate in over 160 countries.

Abbott's approach to human rights and modern slavery risk (which includes the identification of and ways to address modern slavery risk) is directed and guided by Abbott. This is aimed at ensuring a consistent approach across Abbott companies.

Supply Chain

Abbott is a multinational business which procures goods and services from approximately 75,000 suppliers in over 150 countries. With a global footprint, we have an opportunity to leverage our supply chain for positive social change.

We maintain a governance structure that provides oversight of supply chain-related activities, including sustainability, reporting up through Abbott's Executive Vice President, Finance, who reports to our Chairman and CEO. We have established global policies that guide our efforts across the supplier life cycle, including supplier selection, performance, and relationship management. Each business is responsible for

¹ Supplier Guidelines: www.abbott.com/partners/suppliers.html; Position Statement on Human Rights: <http://www.abbott.com/policies/other-disclosures.html>

their respective supply chain, with enterprise efforts coordinated through Abbott's Global Operations Council (GOC).

The GOC collaborates across the enterprise to set the framework for our supply chain, encompassing manufacturing, procurement, and logistics. Several additional groups assist the GOC in our efforts to improve supply chain adaptability, resilience, and flexibility.

Policies, Employee Training, and Due Diligence Process

Policies

Our approach to identifying, assessing, addressing, and managing human rights and modern slavery risk is guided by company-wide policies and processes. These policies and processes are embedded across our business (including Abbott UK) and, in relation to our supply chains, are overseen by the GOC. This ensures a consistent approach towards mitigating modern slavery risk.

Abbott UK, as a member of Abbott's global supply chain, relies on intra-group processes to assess and address its modern slavery risk. The policies and processes which are listed below detail the actions in place to assess and address modern slavery risk in our operations and supply chains. More detailed descriptions of our activities in this area are also available in our most recent Global Sustainability Report.²

Policies and Practices Concerning Modern Slavery	
Code of Business Conduct	https://www.abbott.com/investors/governance/code-of-business-conduct.html
Position Statement on Human Rights	www.abbott.com/policies/other-disclosures.html
Supplier Guidelines	www.abbott.com/partners/suppliers.html
Diversity and Inclusion	www.abbott.com/careers/diversity-and-inclusion.html
Incident Reporting and Investigations	http://speakup.abbott.com

Unless otherwise stated, these policies and processes are applied across Abbott's global supply chain, including the entities covered by this Statement. Our policies are publicly available on Abbott's global website.

Employee Training

Every Abbott employee is expected to adhere to all applicable laws and Abbott's policies, procedures, principles, and standards. Abbott employees are obliged to comply with Abbott's Code of Business Conduct. Our Code of Business Conduct prohibits illegal and inappropriate labour conditions, and cruel or inhumane treatment.

Certain procurement professionals and other stakeholders also undergo mandatory training on modern slavery, forced labour, child labour, and human rights.

Due Diligence Process

Our due diligence and risk assessment processes not only aim to identify modern slavery risk, but they also assist us in addressing and assessing these risks, taking into account the likelihood of modern slavery and the potential negative impact. These processes evaluate suppliers for potential sustainability issues, including those related to human rights and labour, health and safety, environment, and management systems.

When selecting suppliers, we consider applicable environmental, social and governance (ESG) factors alongside business capabilities and capacities, quality management systems, financial health, and alignment with our vision.

²Abbott's latest Global Sustainability Report is available at: www.abbott.com/responsibility/sustainability/sustainability-reporting/current-reports.html.

Our Supply Chain Sustainability Due Diligence programme takes a risk-based approach to screening, assessment, and monitoring, considering supplier size, industry, and sourcing location(s). Insights collected through our Supply Chain Sustainability Due Diligence programme support better supplier engagement and inform sustainability initiative development at the supplier, sourcing, and/or business levels. Our supply chain initiatives prioritise topics such as the environment and human rights and labour, and drive collective action in two ways:

- (1) Issue-specific initiatives: Cover the supply chain and address targeted topics, such as supplier diversity and emissions, water, and inbound materials management, and
- (2) Sourcing category, business, and region-specific initiatives cover multiple risks and opportunities in high-sustainability-risk areas.

We continue to proactively identify and mitigate potential human rights impacts across our operations and supply chain, as well as risks of discrimination and unequal pay, unsafe working conditions, human trafficking, child labour, and forced or bonded labour. As detailed further below, Abbott conducts periodic reviews of our risk exposure, including annual risk assessments.

We engage with our suppliers of potentially high sustainability risk to assess compliance with our Supplier Guidelines. Desktop assessments, conducted by a third party, are tailored to the nature of the supplier's operations, location, and size. Assessments cover the topics of forced labour, child labour, human rights, environment, and sustainable procurement. On-site audits are conducted by an external auditor using the Workplace Conditions Assessment (WCA) or other globally recognised sustainability audit standards to assess social and labour conditions, and health and safety, environment, and business practices at the site. Additional risk-specific analyses are performed for strategic sourcing categories and regions when potential risks are identified. Insights from these programmes then inform our sourcing strategy and contingency plans.

We also address human rights risk in our other business relationships, including through our Third- Party Compliance Process, which requires Abbott businesses, subsidiaries, and affiliates outside the U.S. to complete due diligence before engaging third-party companies. This includes screening companies, identifying high-risk partners, and monitoring and mitigating potential risks.

Effectiveness of Our Programme

We continue to refine and improve our approach to assessing effectiveness. For the 2023 Supply Chain Sustainability Due Diligence programme, Abbott (which includes Abbott UK) assessed the effectiveness of its actions in the following ways:

- (1) Abbott completed inherent sustainability risk screening of strategic suppliers utilising a third-party supply chain sustainability risk screening technology to assign sustainability risk intensity factors based on a supplier's industry and region. Through this exercise, we screened 90% of spend affiliated with raw materials, components and services that are directly traceable to Abbott's final finished products. Results of this preliminary screening drive prioritisation and supplier engagements in 2024.
- (2) In 2023, our due diligence programme evaluated more than 900 potentially high-sustainability-risk suppliers through desktop assessments and, where necessary, performed onsite audits of high-sustainability-risk suppliers. We also engaged with select suppliers to address employee health and safety, environment, and supply chain management issues.
- (3) We also continued partnering with suppliers from key sourcing categories, engaging over 4,000 suppliers on sustainability risks and opportunities.

Reporting Mechanism


Internal and external parties can confidentially and anonymously raise concerns of potential modern slavery by using Abbott's Speak Up tool. Speak Up is available in 16 languages and can be accessed by telephone, email, or internet 24 hours a day, seven days a week. Speak Up can be found here: <http://speakup.abbott.com>.

Board Approval


This Statement is made pursuant to section 54(1) of the Modern Slavery Act 2015 and constitutes Abbott's slavery and human trafficking statement for the financial year ending 31 December 2023. This Statement was approved by the Board of Directors of each entity listed in this Statement and is signed on behalf of their respective Boards by the below directors.

DocuSigned by:


Neil Harris
Director
Abbott Laboratories Limited

DocuSigned by:


Shaun Julian Smith
Director
Abbott Diabetes Care Limited

DocuSigned by:


Ross Iain Campbell
Director
Abbott Medical U.K. Limited

DocuSigned by:
David Bond

David Bond
Director
Abbott Rapid Diagnostics Limited